EUVIMEDEUVIMED entdecken
Crossref

Prognostic Value of [ 18 F]FDG PET Combined with [ 68 Ga]Ga-PSMA PET as Pretreatment Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [ 177 Lu]Lu-PSMA-617

Adam Bekkhoucha, Timothée Zaragori, Pierre Olivier, Marine Claudin, Pierre-Yves Marie, Julien Kunsch, Antoine Verger, Perrine Raymond, Sébastien Heyer, Laetitia Imbert, Caroline Boursier

Journal of Nuclear Medicine · 2026-11 · 67 (11) · 1797-1803

DOI: 10.2967/jnumed.126.273113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 13.08.2026. Verfasst von Adam Bekkhoucha und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, CHRU Nancy, Nancyclotep Imaging Platform, Nancy, France. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Heterocyclic Compounds, 1-Ring, Prostatic Neoplasms, Castration-Resistant, Dipeptides. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy with [177Lu]Lu-PSMA-617 has reshaped the management of metastatic castration-resistant prostate cancer (mCRPC). This study aimed to assess the added prognostic value of [18F]FDG PET beyond [68Ga]Ga-PSMA-11 PET as pretreatment imaging and to develop an overall survival (OS) nomogram for patients with mCRPC who were treated with [177Lu]Lu-PSMA-617.

Methods

From February 2022 to November 2023, all patients with mCRPC treated with at least 1 cycle of [177Lu]Lu-PSMA-617 were analyzed. Baseline [68Ga]Ga-PSMA-11 and [18F]FDG PET parameters (SUVmax, SUVmean, total metabolic tumor volume [TMTV], and total lesion activity) were extracted for both tracers. OS was modeled using 2 hierarchical least absolute shrinkage and selection operator Cox models: clinical covariates plus [68Ga]Ga-PSMA-11 PET (M-PSMA) and clinical covariates plus [68Ga]Ga-PSMA-11 PET plus [18F]FDG PET (M-PSMA + FDG). Model discrimination was assessed using the optimism-corrected Harrell concordance index (C-index), whereas model improvement was assessed with changes in the C-index.

Results

The study included 99 patients with mCRPC, and the median OS was 14 mo (95% CI, 11.7-18.2 mo). In M-PSMA, the [68Ga]Ga-PSMA-11 PET SUVmean was the only significant imaging parameter (hazard ratio, 0.897; 95% CI, 0.852-0.945; P < 0.001). The addition of TMTV [18F]FDG PET in M-PSMA + FDG yielded a modest improvement in prognostic performance (ΔC-index, 0.010; 95% CI, -0.021 to 0.044) but a refined risk prediction for patients with a high TMTV [18F]FDG burden. The final model was used to construct a nomogram for predicting 12-mo OS probability.

Conclusion

Quantitative [68Ga]Ga-PSMA-11 PET parameters provide strong prognostic stratification in patients with mCRPC who were treated with [177Lu]Lu-PSMA-617. Tumor burden, as measured on [18F]FDG PET, adds incremental prognostic information beyond [68Ga]Ga-PSMA-11 PET, resulting in a modest improvement in risk prediction and potential refinement of prognosis in selected high-risk patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Heterocyclic Compounds, 1-RingProstatic Neoplasms, Castration-ResistantDipeptidesLutetiumPositron-Emission TomographyHeterocyclic CompoundsHumansMalePrognosisGallium RadioisotopesGallium IsotopesAgedNeoplasm MetastasisMiddle AgedRadiopharmaceuticalsAged, 80 and overRetrospective StudiesEdetic AcidRadioisotopesProstate-Specific Antigen

Stichwörter der Autor:innen

[177Lu]Lu-PSMA-617[18F]FDG PET[68Ga]Ga-PSMA-11 PETnomogramradiopharmaceutical therapy

Substanzen

Fluorodeoxyglucose F18Heterocyclic Compounds, 1-RingDipeptidesGallium RadioisotopesLutetiumGallium IsotopesHeterocyclic Compoundsgallium 68 PSMA-11PSMA-617Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, CHRU Nancy, Nancyclotep Imaging Platform, Nancy, France.
  • CHRU Nancy, INSERM, Université de Lorraine, CIC 1433, Innovation Technologique, Nancy, France.
  • IADI, INSERM U1254, Université de Lorraine, Nancy, France; and.
  • Department of Endocrinology, CHRU Nancy, Nancy, France.
  • Department of Nuclear Medicine, CHRU Nancy, Nancyclotep Imaging Platform, Nancy, France; c.boursier@chru-nancy.fr.

Zitieren

APA

Bekkhoucha, A., Zaragori, T., Olivier, P., Claudin, M., Marie, P. Y., Kunsch, J., Verger, A., Raymond, P., Heyer, S., Imbert, L., & Boursier, C. (2026). Prognostic Value of [ 18 F]FDG PET Combined with [ 68 Ga]Ga-PSMA PET as Pretreatment Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [ 177 Lu]Lu-PSMA-617. Journal of Nuclear Medicine, 67(11), 1797-1803. https://doi.org/10.2967/jnumed.126.273113

Vancouver

Bekkhoucha A, Zaragori T, Olivier P, Claudin M, Marie PY, Kunsch J, et al. Prognostic Value of [ 18 F]FDG PET Combined with [ 68 Ga]Ga-PSMA PET as Pretreatment Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [ 177 Lu]Lu-PSMA-617. Journal of Nuclear Medicine. 2026;67(11):1797-1803. doi:10.2967/jnumed.126.273113

BibTeX
@article{Bekkhoucha2026,
  author = {Bekkhoucha, Adam and Zaragori, Timothée and Olivier, Pierre and Claudin, Marine and Marie, Pierre-Yves and Kunsch, Julien and Verger, Antoine and Raymond, Perrine and Heyer, Sébastien and Imbert, Laetitia and Boursier, Caroline},
  title = {Prognostic Value of [ 18 F]FDG PET Combined with [ 68 Ga]Ga-PSMA PET as Pretreatment Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [ 177 Lu]Lu-PSMA-617},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  volume = {67},
  number = {11},
  pages = {1797--1803},
  doi = {10.2967/jnumed.126.273113}
}
Kostenlos starten →